Retrophin Inc is a fully integrated biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases.

You can sell covered calls on RETROPHIN INC to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for RTRX (prices last updated Thu 4:16 PM ET):

Last Change Bid Ask Volume P/E Market Cap
24.78 +1.32 24.78 31.50 193K - 1.0B
Covered Calls For RETROPHIN INC (RTRX)
Expiration Strike Call Bid Net Debit Return
If Flat
Return If Flat
Dec 21 25 1.25 30.25 -17.4% -171.6%
Jan 18 25 2.55 28.95 -13.6% -76.4%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Retrophin, Inc. operates as a development stage company, which develops pharmaceutical products for the treatment of rare diseases. It currently focuses on the discovery and development of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options. The company is currently focused on several catastrophic diseases, including Focal Segmental Glomerulosclerosis, Pantothenate Kinase-Associated Neurodegeneration and others. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.